MMJ is currently engaged in litigation with the Drug Enforcement Administration (DEA). The company contends that the DEA has obstructed domestic cannabis research despite the Right To Try and the Medical Marijuana Research Expansion Act. MMJ accuses the DEA of bias in restricting MMJ to cultivate its proprietary marijuana cultivars necessary for research and pharmaceutical drug manufacturing. A pending federal court ruling in Rhode Island will set a significant precedent, challenging DEA authority and potentially easing regulatory barriers for MMJ's future cannabinoid drug development.

MEET DEA DIVERSION Thomas Prevoznik - The man behind the DEA marijuana scam- He Defied Presidential Mandates on Cannabis Research and Right to Try 

The DEA has violated the Controlled Substances Act (CSA) and the Medical Marijuana and Cannabidiol Research Expansion Act by failing to approve MMJ's marijuana research and cultivation application in a timely manner. Anne Milgram, DEA administrator, is responsible for the delays. MMJ claims the DEA has caused significant  harm to suffering patients and financial damages to the company despite adhering to all the DEA regulatory requirements.